Clinical trial NCT06051123: Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients
Official title: Effects of Probiotics on Lipidomic Profile and Disease Evolution in ALS-FTDSD Patients: A Randomized Multicenter, Double-blind, Phase II, Placebo-controlled, Parallel Trial.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: ALSFTD
Keywords: ALS
FTD
motor function
probiotics
lipidomics
metabolites
neurofilament
microbiome
Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Sponsor class: OTHER
Collaborators: name: Lallemand Health Solutions
First posted: 2023-09-22
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Phase 2 study
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants receiving the placebo at different time points.

Detailed description: Individuals with ALS-FTDSD and healthy individuals can participate in this randomized, double-blind, parallel, placebo-controlled study. Participants will be enrolled for a period of 32 weeks, with an intervention period of 24 weeks. For ALS-FTDSD participants, there will be 9 visits during the intervention (5 in-person and 4 phone calls) and 1 follow-up call post-intervention. For healthy participants, there will be 4 in-person visits. For all participants, in-person visits will involve filling out questionnaires, giving blood samples, and returning stool samples.

Eligibility criteria: Inclusion Criteria:

ALS participants:

1. Aged 18 years old or greater.
2. Diagnosis of ALS by El Escorial Criteria revised (possible, probable, probable with lab support and definite).
3. Onset of weakness or speech impairment no more than 24 months before randomization.
4. ALSFRS-R equal or superior to 24/48 at screening, with no more than one subscore under 2/4. ALSFRS-R slope of decline of at least 0.5 points per month on the ALSFRS- R, calculated as (48-score at screening)/ (months since onset of weakness).
5. SVC greater than or equal to 60% predicted for sex, age and height at screening.
6. Note on FTD Symptoms: The presence of FTD symptoms is not a requirement for inclusion in this study. Participants with a diagnosis of ALS, whether or not accompanied by FTD symptoms, are eligible for inclusion. No prior or screening diagnosis of FTDSD is required.
7. Subject has an informant/caregiver who has frequent and sufficient contact to provide accurate information about the patient's cognitive abilities and behaviors to complete the ALS-CBS.
8. Participants apt to comprehend and sign the ICF.
9. Participants of child-bearing potential must have a negative urine pregnancy test at screening and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

   1. Abstinence or agrees to use contraception if planning to become sexually active.
   2. Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant
   3. Double-barrier method
   4. Intrauterine devices
   5. Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
   6. Vasectomy of partner at least 6 months prior to screening
10. Willing to maintain eating habits throughout the study.
11. Willing to refrain from consuming probiotic supplements and food containing added probiotics and/or prebiotics (e.g., yogurts with live, active cultures or supplements) from the moment of screening until the end of the study.

Healthy controls:

1. Aged 18 years old or greater.
2. Able to comprehend and willing to sign ICF.
3. Participants of child-bearing potential must have a negative urine pregnancy test at screening and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

   1. Abstinence or agrees to use contraception if planning to become sexually active.
   2. Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant
   3. Double-barrier method
   4. Intrauterine devices
   5. Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
   6. Vasectomy of partner at least 6 months prior to screening
4. Willing to maintain eating habits throughout the study.
5. Willing to refrain from consuming probiotic supplements and food containing added probiotics and/or prebiotics (e.g., yogurts with live, active cultures or supplements) from the moment of screening until the end of the study

Informants/caregivers:

1. Aged 18 years old or greater.
2. Has frequent and sufficient contact to provide accurate information about the patient's cognitive abilities and behaviors to complete the ALS-CBS.
3. Able to comprehend and willing to sign ICF.

Exclusion Criteria:

ALS Participants:

1. Use of respiratory support (non-invasive ventilation or mechanical respiratory support) at screening.
2. Significant medical condition or behavioral issues that could interfere with participation in the clinical trial in the principal investigator's opinion.
3. Use of a feeding tube at randomization.
4. Use of lipid-lowering drugs for less than 3 months before randomization.
5. Introduction of lipid-lowering drug unless it is due to the event of acute coronary syndrome or stroke as per Canadian guidelines.
6. Use of edaravone with stable dosage for less than 2 months before randomization.
7. Use of riluzole, or ALBRIOZA™ with stable dosage for less than 1 month before randomization.
8. Introduction of edaravone, riluzole or ALBRIOZA™ during the clinical trial.
9. Immunodeficiency (immune-compromised and immune-suppressed participants, e.g., AIDS, lymphoma, participants undergoing long-term corticosteroid treatment, chemotherapy and allograft participants).
10. Pregnancy (as per serum HCG pregnancy test at screening), planning to be pregnant or currently breastfeeding.
11. Use of probiotics other than the study medication in the month prior to randomization.

    Note: participants could be eligible to participate after a 4-week washout period.
12. Use of any antibiotic drug in the month prior to randomization. Note: participants could be eligible to participate after a 4-week washout period.
13. Milk and soy allergy, or severe lactose intolerance.
14. Currently enrolled in another clinical trial.

Healthy Participants:

1. Use of lipid-lowering drugs for less than 3 months before randomization.
2. Introduction of lipid-lowering drug unless it is due to the event of acute coronary syndrome or stroke as per Canadian guidelines.
3. Pregnancy (as per serum HCG pregnancy test at screening), planning to be pregnant or currently breastfeeding. Note: participants will not take the IP or placebo, but pregnancy is a major factor that could affect lipidomic profiling.
4. Use of probiotics in the month prior to day 0 of the study (visit 2). Note: participants could be eligible to participate after a 4-week washout period. Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group.
5. Use of any antibiotic drug in the month prior to day 0 of the study (visit 2). Note:

   participants could be eligible to participate after a 4-week washout period. Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group.
6. Milk and soy allergy, or severe lactose intolerance. Note: Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group. We aim to exclude allergies, so participants are maintained on standard diet.
7. Currently enrolled in another clinical trial.

Primary outcomes:
measure: Change in lipidomic profiles
timeFrame: 24 weeks
measure: Change in polar metabolite profiles
timeFrame: 24 weeks
Secondary outcomes:
measure: Change in ALSFRS-R score
timeFrame: 24 weeks
measure: Change in ALS-CBS score
timeFrame: 24 weeks
measure: Change in FAB score
timeFrame: 24 weeks
measure: Change in neurofilament light chain concentration
timeFrame: 24 weeks
measure: Change in ALSAQ-5 scores
timeFrame: 24 weeks
measure: Change in fecal microbiota in ALS-FTDSD patients
timeFrame: 24 weeks
measure: Polar metabolite profiles of healthy participants
timeFrame: 24 weeks
measure: Lipidomic profiles of healthy participants
timeFrame: 24 weeks
measure: Fecal microbiota of healthy participants
timeFrame: 24 weeks
Other outcomes:
measure: Number of AEs and SAEs
timeFrame: 28 weeks
measure: Changes in lab safety marker: Complete Blood Count (CBC)
timeFrame: 24 weeks
measure: Changes in lab safety markers: Liver Function Test (LFT) - ALT
timeFrame: 24 weeks
measure: Changes in lab safety markers: Liver Function Test (LFT) - AST
timeFrame: 24 weeks
measure: Changes in lab safety markers: Liver Function Test (LFT) - bilirubin
timeFrame: 24 weeks
measure: Changes in lab safety marker: creatinine
timeFrame: 24 weeks
Locations:
city: Montréal
country: Canada
facility: Centre Hospitalier de l'Université de Montréal
state: Quebec
Study officials:
affiliation: CRCHUM
name: Genevieve Matte, MDCM, FRCP
role: PRINCIPAL_INVESTIGATOR
References: